Phoenix Biotech Acquisition Corp.
PBAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.34 | -0.07 |
| FCF Yield | -43.31% | -161.91% | -1.53% | -1.53% |
| EV / EBITDA | -1.45 | -0.15 | -57.93 | -35.18 |
| Quality | ||||
| ROIC | 120.78% | 981.50% | -477.30% | 4,542.66% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.85 | 0.87 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 30.67% | -3.99% | 0.16% | -18.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.46 | 0.78 | 0.21 |
| Interest Coverage | -734.94 | -342.90 | -5,824.15 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |